Araris Biotech AG

About Araris Biotech AG

Araris Biotech AG is a spin-off from the Paul Scherrer Institute (PSI) and ETH Zurich, focused on pioneering the development of novel antibody-drug conjugate (ADC) technologies. Their mission is to create highly homogenous, stable, and potent ADC therapies using proprietary linker technology to improve cancer treatment outcomes.

Products & Services

Araris Linker Technology:A proprietary peptide linker technology that enables site-specific payload attachment to antibodies, resulting in stable, soluble, and high-quality ADCs with simple, cost-effective manufacturing in one step using off-the-shelf antibodies.

Antibody-Drug Conjugates (ADCs):Biopharmaceuticals designed to deliver highly toxic drugs specifically to cancer cells, minimizing damage to healthy tissue, with enhanced stability and efficacy through Araris' linker platform.

Specialties

Antibody-Drug Conjugates (ADCs) Linker Technology Cancer Therapy Bioconjugation Site-Specific Payload Attachment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 2800000 MR: - FA: CHF 2.5M FAN: 2800000	D: 2023-05-05 FD: 2023-05-05	1 investors

Grant Latest

2023-05-05

$2.8M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

Dragan Grabulovski

CEO and Co-founder

P

Philipp Spycher

Co-founder and Chief Scientific Officer (CSO)

I

Isabella Attinger-Toller

Co-founder and Chief Technology Officer (CTO)

M

Martin Behe

Co-founder

R

Rakesh Dixit

Scientific Advisory Board Member

J

John Lambert

Scientific Advisory Board Member

View 11 more team members with Pro

Unlock Full Team Directory

Recent News